LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma.

Female Humans Biomarkers / metabolism Fallopian Tubes / metabolism Ovarian Neoplasms / pathology Proteins / metabolism Long Interspersed Nucleotide Elements

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
27 01 2023
Historique:
received: 16 08 2022
accepted: 25 01 2023
pubmed: 28 1 2023
medline: 1 2 2023
entrez: 27 1 2023
Statut: epublish

Résumé

Long interspersed element 1 (LINE-1) open reading frame 1 protein (ORF1p) expression is a common feature of many cancer types, including high-grade serous ovarian carcinoma (HGSOC). Here, we report that ORF1p is not only expressed but also released by ovarian cancer and primary tumor cells. Immuno-multiple reaction monitoring-mass spectrometry assays showed that released ORF1p is confidently detectable in conditioned media, ascites, and patients' plasma, implicating ORF1p as a potential biomarker. Interestingly, ORF1p expression is detectable in fallopian tube (FT) epithelial precursors of HGSOC but not in benign FT, suggesting that ORF1p expression in an early event in HGSOC development. Finally, treatment of FT cells with DNA methyltransferase inhibitors led to robust expression and release of ORF1p, validating the regulatory role of DNA methylation in LINE-1 repression in non-tumorigenic tissue.

Identifiants

DOI: 10.1038/s41598-023-28840-5 PMID: 36707610 PMC: PMC9883229
pubmed: 36707610
doi: 10.1038/s41598-023-28840-5
pii: 10.1038/s41598-023-28840-5
pmc: PMC9883229
doi:

Substances chimiques

Biomarkers 0
Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1537

Subventions

Organisme : NCI NIH HHS
ID : U24 CA270823
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Bioinformatics. 2014 Sep 1;30(17):2521-3
pubmed: 24813211
Am J Obstet Gynecol. 2012 Apr;206(4):351.e1-8
pubmed: 22284961
Nat Rev Genet. 2009 Oct;10(10):691-703
pubmed: 19763152
J Invest Dermatol. 2012 Jun;132(6):1689-97
pubmed: 22402438
Clin Cancer Res. 2017 Mar 1;23(5):1263-1273
pubmed: 27573169
Clin Chem. 2009 Jun;55(6):1108-17
pubmed: 19372185
Cancer Discov. 2016 Dec;6(12):1342-1351
pubmed: 27856443
Genes Dev. 2020 Nov 1;34(21-22):1439-1451
pubmed: 33060137
Int J Womens Health. 2013 Dec 20;6:25-33
pubmed: 24379701
Clin Chem. 2017 Apr;63(4):816-822
pubmed: 28188229
ACS Nano. 2020 Aug 25;14(8):9491-9501
pubmed: 32589401
Gynecol Oncol. 2020 Oct;159(1):239-247
pubmed: 32690392
J Clin Invest. 2014 Jun;124(6):2611-25
pubmed: 24762435
Cancer. 2002 Nov 1;95(9):1886-93
pubmed: 12404282
Cancer Res. 2005 Mar 15;65(6):2162-9
pubmed: 15781627
Mol Cell Proteomics. 2011 Apr;10(4):M110.005645
pubmed: 21245105
Lancet. 2021 Jun 5;397(10290):2182-2193
pubmed: 33991479
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):E733-E740
pubmed: 28096347
Lancet. 2016 Mar 5;387(10022):945-956
pubmed: 26707054
Bioinformatics. 2014 Sep 1;30(17):2524-6
pubmed: 24794931
Curr Opin Obstet Gynecol. 2017 Feb;29(1):26-34
pubmed: 27898521
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Cancer Res. 2003 Jul 1;63(13):3695-700
pubmed: 12839961
Int J Gynecol Cancer. 2008 Jul-Aug;18(4):711-7
pubmed: 17944913
Drugs Future. 2013 Aug;38(8):535-543
pubmed: 26190889
Curr Opin Genet Dev. 2012 Jun;22(3):191-203
pubmed: 22406018
Mol Cell Proteomics. 2012 Jun;11(6):M111.013854
pubmed: 22199228
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer Res. 2007 Jul 1;67(13):6400-8
pubmed: 17616700
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2504-2512
pubmed: 33051337
Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):E4894-900
pubmed: 26283398
Proc Natl Acad Sci U S A. 2011 May 3;108(18):7547-52
pubmed: 21502498
Gynecol Oncol. 2014 Feb;132(2):462-7
pubmed: 24374023
Nat Protoc. 2012 Sep;7(9):1755-64
pubmed: 22936217
Ann N Y Acad Sci. 2008 Aug;1137:171-4
pubmed: 18837943
Gynecol Oncol. 2000 Jun;77(3):350-6
pubmed: 10831341
Anal Chem. 2016 Aug 2;88(15):7548-55
pubmed: 27321643
Int J Cancer. 2008 Jul 1;123(1):8-13
pubmed: 18425818
Cancer Res. 2000 Nov 15;60(22):6281-7
pubmed: 11103784
JAMA Intern Med. 2018 May 1;178(5):611-612
pubmed: 29450456
Oncotarget. 2017 Feb 14;8(7):11906-11916
pubmed: 28060757
J Pathol. 2019 May;248(1):41-50
pubmed: 30560554
Mob DNA. 2019 Dec 31;11:1
pubmed: 31892958
Nat Med. 2015 Sep;21(9):1060-4
pubmed: 26259033
J Proteome Res. 2004 Mar-Apr;3(2):235-44
pubmed: 15113099
Hum Pathol. 2019 Oct;92:39-47
pubmed: 31220479
Annu Rev Genet. 2001;35:501-38
pubmed: 11700292
JAMA Oncol. 2015 Nov;1(8):1128-32
pubmed: 26181193
Nat Biotechnol. 2006 Aug;24(8):971-83
pubmed: 16900146
Nat Methods. 2013 Jan;10(1):28-34
pubmed: 23269374
Biomark Med. 2009 Jun 1;3(3):275-288
pubmed: 19684876
Am J Pathol. 2019 Mar;189(3):513-520
pubmed: 30553834
Cell Rep. 2018 Jun 26;23(13):3730-3740
pubmed: 29949758
Oncotarget. 2014 May 30;5(10):3115-29
pubmed: 24833108
Int J Mol Sci. 2018 Dec 12;19(12):
pubmed: 30545144
Nature. 2001 Feb 15;409(6822):860-921
pubmed: 11237011
Nucleic Acids Res. 2010 Jul;38(12):3909-22
pubmed: 20215437
Am J Pathol. 2014 May;184(5):1280-6
pubmed: 24607009
Nat Commun. 2017 Oct 23;8(1):1093
pubmed: 29061967
Gynecol Oncol. 2017 Dec;147(3):642-647
pubmed: 29032825
Cancers (Basel). 2020 Mar 24;12(3):
pubmed: 32213861
Nat Rev Cancer. 2017 Jul;17(7):415-424
pubmed: 28642606
Mol Cell Proteomics. 2007 Dec;6(12):2212-29
pubmed: 17939991
Gynecol Oncol. 2018 Jun;149(3):585-591
pubmed: 29572027

Auteurs

Sho Sato (S)

Penn Ovarian Cancer Research Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 19104, USA.

Michael Gillette (M)

The Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.
Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, 02114, USA.
Harvard Medical School, Boston, MA, 02115, USA.

Pamela R de Santiago (PR)

Penn Ovarian Cancer Research Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 19104, USA.

Eric Kuhn (E)

The Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.

Michael Burgess (M)

The Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.

Kristen Doucette (K)

The Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.

Yi Feng (Y)

Penn Ovarian Cancer Research Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 19104, USA.

Carlos Mendez-Dorantes (C)

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.

Paul J Ippoliti (PJ)

The Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.

Sara Hobday (S)

Penn Ovarian Cancer Research Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 19104, USA.

Marilyn A Mitchell (MA)

Penn Ovarian Cancer Research Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 19104, USA.

Kai Doberstein (K)

Penn Ovarian Cancer Research Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 19104, USA.

Stefan M Gysler (SM)

Penn Ovarian Cancer Research Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 19104, USA.

Michelle S Hirsch (MS)

Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Harvard Medical School, Boston, MA, 02115, USA.

Lauren Schwartz (L)

Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 19104, USA.

Michael J Birrer (MJ)

Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 35233, USA.

Steven J Skates (SJ)

Harvard Medical School, Boston, MA, 02115, USA.
Biostatistics and Computational Biology, Massachusetts General Hospital, Boston, MA, USA.

Kathleen H Burns (KH)

Harvard Medical School, Boston, MA, 02115, USA.
Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.

Steven A Carr (SA)

The Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.
Harvard Medical School, Boston, MA, 02115, USA.

Ronny Drapkin (R)

Penn Ovarian Cancer Research Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 19104, USA. rdrapkin@pennmedicine.upenn.edu.
Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 19104, USA. rdrapkin@pennmedicine.upenn.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › LINE-1 ORF1p as a candidate biomarker in high...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › LINE-1 ORF1p as a candidate biomarker in high...
questionsmedicales.fr › Structures anatomiques de l'animal › Oviductes › Trompes utérines › LINE-1 ORF1p as a candidate biomarker in high...
questionsmedicales.fr › Maladies endocriniennes › Troubles gonadiques › Maladies ovariennes › Tumeurs de l'ovaire › LINE-1 ORF1p as a candidate biomarker in high...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › LINE-1 ORF1p as a candidate biomarker in high...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Séquences répétées dispersées › Rétroéléments › Éléments LINE › LINE-1 ORF1p as a candidate biomarker in high...